EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

May 18, 2026

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 35 min

What were the key takeaways from EL.En. S.p.A.'s May 18, 2026 earnings call?

In the first quarter of fiscal year 2026, EL.En. S.p.A. reported total revenues of approximately EUR 145 million, reflecting a 3.3% increase year-over-year. The medical sector drove this growth with a 9.3% revenue increase, while the industrial sector saw an 11.4% decline. Management maintained its revenue growth guidance of approximately 5% for the full year, signaling confidence despite macroeconomic challenges.

What topics did EL.En. S.p.A. cover?

  • Medical Sector Performance: The medical sector achieved a revenue increase of 9.3%, contributing significantly to overall growth. Management noted, "more than 10% on an organic base neutralizing the effect of the exit of our Japanese subsidiary," indicating strong underlying demand.
  • Industrial Sector Challenges: The industrial sector experienced an 11.4% decline in sales, primarily due to a 15.5% drop in the cutting segment. Management acknowledged, "Sales have been lagging in this quarter in the Industrial sector," highlighting ongoing challenges.
  • EBIT Margin Improvement: EBIT improved to EUR 19.8 million, with an EBIT margin of 13.6%, up from 12.5% in Q1 2025. Management stated, "this was an excellent achievement due to the weak seasonality of the first quarter," reflecting operational efficiency gains.
  • Cash Flow and Financial Position: The net financial position increased by EUR 1.5 million, a notable improvement for a typically cash-absorbing quarter. Management emphasized, "the first quarter that historically is a cash absorber," indicating better cash management.
  • Guidance Confirmation: Management confirmed guidance for 2026, targeting a consolidated revenue growth of about 5% and an improvement in EBIT margin. They stated, "we remain cautiously optimistic," despite acknowledging macroeconomic headwinds.

What were EL.En. S.p.A.'s May 18, 2026 results?

  • Revenue: EUR 145 million (vs EUR 140.9 million in Q1 2025, +3.3% YoY)
  • EBIT: EUR 19.8 million (vs EUR 17.4 million in Q1 2025, +14% YoY)
  • EBIT Margin: 13.6% (up from 12.5% in Q1 2025)
  • Gross Margin: 46.1% (vs 44.7% in Q1 2025)
  • Net Financial Position: EUR 173.7 million (up EUR 1.5 million from EUR 172.2 million at year-end 2025)
  • CapEx: EUR 4 million (lower than Q1 2025)

Overall, EL.En. S.p.A.'s Q1 2026 results reflect resilience in the medical sector, though challenges remain in the industrial segment. The confirmed guidance and focus on innovation are positive indicators for future growth. Investors should monitor the industrial sector's recovery and the impact of macroeconomic factors on overall performance.

Earnings Call Speaker Segments

Andrea Cangioli

executive
#1

Good morning, good afternoon, everyone, and thanks for being with us today as we go over the El.En. Group's financial results for the first quarter that closed on March 31st, 2026. Enrico Romagnoli is here on the call alongside me, as Nicola mentioned ahead of time. Looking back over those first 3 months of the year, it's evident the El.En. Group keeps steering through a complicated worldwide environment with resilience and a commitment to our core mission that hasn't changed: using our technological leadership across both the medical and industrial laser sectors to generate value for our partners around the world and, in turn, for our shareholders. Our financial results left us pleased, and I want to thank our worldwide team of engineers, clinicians, and staff for the dedication they show to our group's success. Moving to our consolidated financial performance for Q1 2026, we brought in total revenues of approximately €145 million, which is 3.3% higher than Q1 of the prior year. That performance mirrored the outstanding showing of the medical sector, whose revenues rose 9.3%, and in fact exceeded 10% on an organic basis, offsetting the effect of the departure of our Japanese subsidiary With us, and getting past the industrial sector's slowdown, where sales declined by 11.4%, largely because of the cutting segment, which fell by 15.5% during the quarter.

Andrea Cangioli

executive
#2

This quarter also showed better P&L efficiency, driven both by margin on sales and by leverage, which produced €19.8 million in EBIT at a 13.6% EBIT margin — more than 1 point higher than Q1 2025 and, what's more, an excellent result given how weak the first quarter's seasonality typically is, also higher sequentially versus the last quarter of 2025 on EBIT margin performance. Since leverage comes from volume and margin on sales depends on the quality of the sales mix, I'd like to give you some color on that. The volume increase came entirely from the medical business, and for purely mathematical reasons that helped the overall margin, because margins are higher in medical than in industrial. It's roughly 48% in medical versus 38% in industrial. Within each sector, margins held stable at a high level in medical, but in industrial they improved materially, from 34% in Q1 2025 and 28% in Q4 2025 up to 38% in this first quarter. It's important to point out that under the sales margin profile, we also had a positive contribution from the industrial sector. The margin improvement in the segment is the cornerstone of the path toward returning the segment to stronger profitability.

Andrea Cangioli

executive
#3

On the industrial side, sales have been soft this quarter, but from a margin standpoint we’re moving in the right direction, and we anticipate stronger quarters ahead on the sales volume side as well. The foundation for this trend is the sales mix in terms of product and geographic profile across both sectors. In industrial, geography is a major margin driver, with Europe, the US, and Brazil standing out as the most attractive markets from a margin perspective. Q4 2025 had the highest share of sales in Italy and negligible sales volume in the US and Brazil, and as a result posted a very low gross margin on sales. Q1 2026 saw a return to decent sales volume in Europe and the US, and correspondingly a lower total share of sales in Italy. The impact on margin was clear. Weak sales performance in Brazil this quarter was the missing piece that prevented the material margin improvement from turning into a volume effect large enough to better cover operating expenses. In industrial, as quarterly sales volume in the cutting segment fell, higher-margin sales in the marking and laser sources segment grew their weight, thereby lifting segment margins.

Andrea Cangioli

executive
#4

Medical kept its gross margin levels where they were, which confirms a sales mix favoring anti-aging treatments over hair removal within aesthetic devices, and it also confirmed how materially the surgical business contributes, both on system sales and on consumable sales, since the volume of sterile fiber sold during the quarter once again went past the 10 million threshold. Onda PRO is right now the trendiest device in our product range, a system that successfully captures what demand in medical aesthetics requires, with particular focus on skin tightening and skin firming. Our Coolwaves microwave technology makes possible minimally invasive and extremely effective procedures whose effects are evident yet also respectful of how the patient looks, mild improvements that do not distort the expression. Patients want to improve their appearance, but they are no longer willing to accept that their efforts are too evident. They want their status maintained without being noticed too much. By the way, on Onda PRO, we expect an unprecedented number of imitations being brought to market, and we are putting in a notable effort both on the marketing and commercial side and on the legal side to protect the uniqueness of our flagship device. On the innovation side, our key success factor and main competitive weapon, we continue to dedicate significant resources in terms of management, manpower, investments that let our R&D teams maintain their excellent productivity level.

Andrea Cangioli

executive
#5

Looking ahead to this year, we’ll be introducing new aesthetics products aimed at pigmented lesions and hair removal, along with enhanced capabilities for our skin tightening devices. On the surgery side, a new laser operating in the blue wavelength range is scheduled for release by the end of the year, and in urology, a new high-power thulium BPH system is nearly set for launch. In the industrial segment, our laser cutting systems have been upgraded, particularly the large-size, high-power systems intended for steel construction, and our laser marking offering is continually refreshed with new wavelengths and special emission modes that make these systems increasingly innovative and increasingly tailored to the needs of a diverse set of customers, application segments, and industries. A quick note on the unprecedented improvement in net financial position during the first quarter. We were up €1.5 million in the quarter — the first quarter that historically absorbs cash. Enrico will walk you through the details. I can now note that CapEx in Q1 '26 was lower than in Q1 '25, as expected to date on a yearly basis as well — excuse me, as expected to date and as expected on a yearly basis as well.

Andrea Cangioli

executive
#6

Last week, we approved a rather sizable investment for a new building here at the Calenzano plant, one that will be mainly dedicated to marketing and support areas for welcoming potential customers, both in person and with the most recent technologies for effective remote meetings. The order of magnitude of the investment is around €5 million. It won't change the outlook of our cash flow statement, but it will probably bring 2026's CapEx closer or equal to the order of magnitude we had in 2025. I would also like to give you an update on certain possible M&A activities I outlined in other meeting and calls. Quanta System's new subsidiary in the US for the medical-surgical business is now operational, and with a seasoned general manager, we are hopeful of being able to rapidly capture the market and the customer base that was previously covered through a distributor. The launch of the company didn't exactly follow the plan, and also the transition with the former distributor required an initial investment smaller than budgeted. Quanta's management is following closely the development of the company, and we will update you on the performance of this new sub of Quanta System. Also, in the physiotherapy segment, we are working to an agreement with our US distributor with the goal of a closer cooperation and subsequently an increase in the performance on this market segment, one of the most fruitful among the businesses of ASA, the company based in Vicenza which is dedicated to this market segment.

Andrea Cangioli

executive
#7

On the industrial and medical side of other M&A activity — one part being laser cutting, the other distribution of medical laser systems in selected countries — there's nothing notable for me to report, except that the group is looking into possibly assessing certain options in that regard. Over the quarter, the group carried on with and further strengthened its sustainability work, which also sits among the performance indicators tied to management's incentive systems. Rollout of the 2023 to 2027 Sustainability Plan went on, with overall progress matching the objectives set and, in some areas, going beyond them — especially on initiatives for shifting to renewable energy sources. The plan keeps its focus on strategic matters like combating climate change, the circular economy, fostering a responsible supply chain, building human capital, and backing local communities, which confirms the group's dedication to a sustainable development model fully woven into business processes. As we foreshadowed in the press release we put out to disclose the news, today we're sharing more detail regarding the resignation that our General Manager, Mr. Paolo Salvadeo, formally handed in for personal reasons on April 30th. Dr. Salvadeo held this role since 2017, and his impact on our group has been profound.

Andrea Cangioli

executive
#8

During his time leading the company, El.En. has strengthened its standing as a worldwide leader—particularly in the medical segment, which has been the center of his managerial work. I already expressed this personally, of course, but today, representing the Board of Directors, I would like to offer Paolo formal thanks for his outstanding professionalism and for the major role he has played in our expansion across multiple dimensions, among them the reinforcement of our managerial framework during the past 7 years. We wish him only the best going forward. Beyond noting that we know of no cause—other than purely private ones—behind Paolo's choice to step down, and that our relationship with him is excellent, I want to highlight a few key matters about the transition period now before us. On operational continuity: because of the solid management structure that Dr. Salvadeo was instrumental in establishing, we are lucky to have a management team of remarkable talent and professionalism. Given how strong this team is, we anticipate no effect on our daily efficiency or on operational continuity. As for our strategic targets, our dedication to those goals has not changed. Nothing has shifted in our targets, whether short- or mid-term.

Andrea Cangioli

executive
#9

We're continuing to push ahead with the very same drive and concentration we had at the start of the year. As for what comes next, executive management has given the Board of Directors its perspective regarding the new management structure. We can confirm that, as of right now, there are no plans in place to fill the General Manager role with a replacement. Indeed, also owing to the contribution of the General Manager Paolo Salvadeo, the management know-how and synergies already present let the company forgo a direct replacement at this moment. The company is able to count effectively on chosen executive positions that are already established throughout the different business areas, and these roles complement one another. Final coordination will stay the responsibility of the executive directors, specifically the President and the Managing Director. Right now, I'll hand things over to Enrico for his comments, the detailed comments on the financials.

Enrico Romagnoli

executive
#10

Thanks, Andrea. Morning, everyone. I’ll give a quick rundown of the first-quarter financial results. During the first quarter, the group posted revenue growth of 3.3%, coming in at €145.6 million versus €140.9 million in the same period last year. The medical sector delivered the main performance, while industrial showed a decline of roughly 11%. On a like-for-like basis, medical sector revenue growth would have been even stronger, hitting almost 11%, as With us, consolidated through the end of February 2025, added about €1.5 million to medical service revenue in the prior period. In 2026, weakness in the US dollar across medical, and industrial as well, had a cumulative negative effect on sales growth of -1.6%, amounting to €2.3 million. Gross margin came to €67.2 million, rising roughly 7% from €62.9 million on March 2025, with the margin rate increasing from 44.7% to 46.1% in the first quarter of 2026. Even though the medical sector posted the highest sales margin, the quarter’s sales margin improvement was also recorded in the industrial sector. Despite lower turnover, the sales mix in industrial was more favorable, both geographically—with a smaller share from the highly competitive Italian market—and by product type, helped by a reduced weighting of the laser cutting segment, which carries a lower margin than laser sources and laser marking.

Enrico Romagnoli

executive
#11

Operating expenses rose both in absolute terms and in how much they weighed on sales — chiefly G&A, up 6%, which includes travel and IT costs, along with sales and marketing activities, up 12%, largely because of trade fairs. Staff cost went up as headcount grew. As of March 2026, employees numbered 1,428, versus 1,383 in March 2025 — an increase of 45 units across Italy and Europe, in both medical and industrial. EBITDA came in at €23.7 million, a 9% rise from the €21.7 million posted last quarter. EBIT was positive at €19.8 million, 14% higher than the €17.4 million of the prior year. That gain mirrors both a better gross margin and a smaller drag on sales from depreciation, amortization, and other provisions — principally thanks to a lower bad debt provision. The biggest decrease stems from Asclepion and With us, which were consolidated through February 2025. With us weighed negatively on EBIT 2025 to the tune of €0.65 million. Financial management produced a gain of €0.8 million, against a loss of €1.1 million a year earlier. Exchange rate differences swung from a loss of roughly €1.5 million booked in the first quarter 2025 to a profit of €0.6 million booked in the first quarter 2026.

Enrico Romagnoli

executive
#12

The associated companies' contribution, which is included in other expenses, came in negative at €0.7 million, mainly because of With us and Penta Laser Zhejiang, each at -€0.2 million. During 2025, the majority stake in these two companies was sold. Elesta, by contrast, posted a positive contribution of €95,000. El.En. recognized an additional impairment through a 50% write-down of its stakes in Epica International for €0.4 million. Lastly, pretax was positive at €20 million, up from €16.3 million on March 2025. Turning now to the cash flow analysis, the net financial position rose by €1.5 million in the quarter, from €172.2 million as of December 2025 to €173.7 million on March. The increase in net working capital absorbed €9 million, while roughly €5 million was absorbed by changes in other assets and liabilities, including higher advances paid to supplier, lower advances received from customer, and an increase in VAT receivable from the tax authorities. Cash absorption for working capital was therefore lower than that recorded in the first quarter 2025, and capital expenditure amounted to €4 million, also lower than the investment did in the first quarter 2025. On May 27th, a dividend of €0.25 per share will be paid, for a total consideration of €20 million.

Enrico Romagnoli

executive
#13

Turning to the breakdown by business, revenue rose across every medical application segment. The aesthetic segment turned in a strong performance, up 10%, powered by the anti-aging system even though hair removal was weak. Surgical application stayed strong, the physiotherapy system showed a recovery, and medical service revenue — which covers sales of services and consumables generated after a system is installed — rose 8%, with roughly 50% of that medical service revenue tied to sterile optical fiber used in surgical application. Deconsolidation of With us, the Japanese company, produced an inorganic revenue decline for the service segment, so organic growth in that segment, excluding With us, from 2025 sales came to roughly a 16% increase in the quarter. In the industrial sector, quarterly revenue fell 11%, with the decrease hitting system sales across all application segments except for the restoration. Post-sales and components, by contrast, did very well, rising both in absolute terms and as a share of total revenue. On the breakdown by area, the European market was the main driver of revenue growth during the quarter across both application segments in both sectors. The Italian market recorded a decline, while in the rest of the world, performance was positive in the medical sector and down in the industrial sector.

Enrico Romagnoli

executive
#14

Over in Italy, the softer result in medical came largely from professional aesthetics, and we expect that to bounce back once the new hair removal system is launched. On the industrial side, a difficult climate is still weighing on manufacturing and especially on machine tools, partly because uncertainty persists around tax incentives for investment. Those incentives are now being set out over multiple years, which ought to give customers a steadier framework for their investment choices. The drop in industrial sales across the rest of the world is mostly down to the weak showing at Cutlite do Brasil, the company that distributes our laser cutting systems in Brazil. Growth in the industrial market within medical stayed solid, including in countries outside Europe, led in particular by the Far East. Andrea, if you'd like, you can go ahead with the guidance.

Andrea Cangioli

executive
#15

Thanks, Enrico. As we look toward the rest of 2026, we're staying cautiously optimistic. We're keeping an eye on macroeconomic headwinds and supply chain complexities —

Operator

operator
#16

Andrea, did you have something?

Andrea Cangioli

executive
#17

Yes?

Enrico Romagnoli

executive
#18

No, it wasn't audible anymore. It wasn't audible anymore? No.

Andrea Cangioli

executive
#19

We’re keeping macroeconomic headwinds and supply chain complexities in mind, but our order book is still healthy and the pipeline is robust. Q1 2026 has given us a solid foundation for the year, so we can confirm the guidance we released a couple of months ago: we target consolidated revenue growth of about 5%, and, as we did in Q1 2026, we count on improving our EBIT margin on a yearly basis as well. Thank you for listening to our prepared comments. I believe we are ready for your questions now.

Operator

operator
#20

We're ready to begin the Q&A portion now, so please use the virtual hand-raise feature if you'd like to ask something. Go ahead.

Andrea Cangioli

executive
#21

Andrea, perhaps we could have Andrea go first. He's at the top of the list here. Andrea Bonfà.

Operator

operator
#22

Alright. Andrea, please continue, since we don't have anything—Andrea?

Andrea Bonfà

analyst
#23

I've now got access to the audio. Thanks so much for taking my question, Andrea. Very quickly, my curiosity, let's say, centers on those numbers — the first quarter figure. How does that affect RAM procurement, and what visibility do we have on that particular point or aspect? Thank you very much.

Andrea Cangioli

executive
#24

There's no impact at all. We're paying somewhat more for our RAM memories, but as a single component, the RAM's effect isn't material. Right now, lead times are longer, yet we don't see a shortage affecting us. Higher memory costs will certainly raise the cost of our products, but given the volumes we plan to manufacture, at this moment those cost increases are offset by efficiencies improving in other respects, so they have no impact on our gross margin — at least no material impact.

Andrea Bonfà

analyst
#25

Thanks a lot.

Operator

operator
#26

And now it's Carlo Maritano's turn. Please proceed, Carlo.

Carlo Maritano

analyst
#27

Is this coming through? Yes.

Andrea Cangioli

executive
#28

Yes.

Operator

operator
#29

Yes. All right.

Carlo Maritano

analyst
#30

Good afternoon, everyone. Three questions from me. First, on the guidance: if I recall correctly, on the last call you said growth of 5% was expected, and that was largely predicated on roughly equal contributions from the two divisions. I'm curious how Q1 is altering that picture. The 5% now, I'd imagine, leans more toward medical — though please correct me if that's not right. My second question concerns the industrial segment. I'm wondering if the softness there also stems from any accounting factors, perhaps orders not booked by the close of the first quarter that could slip into the second quarter, as has occurred before. The last question is about the Middle East. Could you update us on how business in that region is developing — whether orders are being cancelled or postponed, or whether the stabilization of the situation means no particular difficulties are arising. Thank you. Okay.

Andrea Cangioli

executive
#31

Regarding your first question, yes, we’re reaffirming the guidance, and we’re also reaffirming that both sectors will contribute. For a business like industrial, that first segment covers a very brief valuation window. On your second question, no significant cutoff changes occurred during this quarter. Some deliveries have slowed, and so has the conversion of orders into concrete business — in Brazil, for example — and we anticipate that, and we’re counting on it being recovered.

Carlo Maritano

analyst
#32

Across every part of the business.

Andrea Cangioli

executive
#33

For the year, we can confirm that we expect growth from both segments by the end of the year. Regarding the Middle East situation, there isn't much of an effect this quarter. Ironically, the sales we're missing in the Middle East are mostly hitting the hair removal segment, which is the lowest margin-bearing sales segment, and so when we're putting up with sales in other areas and other disciplines, we replace the lower-margin-bearing sales with higher margin-bearing, which is accretive to the results. For the moment, there are certain countries in the area which continue to buy well, like Egypt. Other countries where we're registering a very strong slowdown, like Saudi Arabia and Iraq in particular. Overall, we're seeing a slowdown, but overall in these months we've always seen that sales traction in other areas of the world is offsetting the slowdown we're seeing in the Middle East area.

Operator

operator
#34

Carlo, any other question from you? Is that all you need?

Carlo Maritano

analyst
#35

Yeah. That's sufficient.

Operator

operator
#36

Thank you. That's all the questions we have. I'd like to check with the investors whether anyone else has a question for the management team. No. There are no further questions right now, though I'd like to ask one more time whether there's another question out there. No.

Carlo Maritano

analyst
#37

Alright.

Operator

operator
#38

That's fine. There's nothing else to ask. Pardon?

Carlo Maritano

analyst
#39

No, no. Sorry.

Andrea Cangioli

executive
#40

Appreciate it.

Operator

operator
#41

Ladies and gentlemen, that brings this conference to a close. Ahead of wrapping up today's call, I'd like to make one last invitation — to the reverse roadshow taking place in Samarate on May 28th, next week, an event many of you have already signed up for. As things stand, 22 investors are registered for it. Tomorrow the final invitation goes out, and anyone who wants to take part can sign up either straight through our platform or by sending me an email to request registration. Should you have any questions going forward, please feel free to reach out to Enrico Romagnoli, who will gladly help you. Thank you for joining this conference, and we hope to see all of you again next time. Goodbye, everybody.

Carlo Maritano

analyst
#42

Thanks. Goodbye.

Andrea Cangioli

executive
#43

Take care.

Operator

operator
#44

Bye. Ciao, ciao. Arrivederci.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.